Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5665104 | 0.81 | — | — | |
| SCHEMBL385268 | 0.81 | — | — | |
| SCHEMBL384440 | 0.80 | — | — | |
| SCHEMBL14312348 | 0.80 | — | — | |
| SCHEMBL335952 | 0.78 | — | — | |
| SCHEMBL3852707 | 0.78 | — | — | |
| SCHEMBL3880408 | 0.77 | NR1H2 (0.36) | — | |
| SCHEMBL383184 | 0.77 | NR1H2 (0.36) | — | |
| SCHEMBL3313998 | 0.76 | — | — | |
| SCHEMBL385025 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858641-B2 | melanocortin-4 receptor (MC4-R) agonists such as (3R,5S)-N-(2-{2-[2-fluoro-4-(methyloxy)phenyl]ethyl}-1-oxo-1,2-dihydroisoquinolin-6-yl)-3,5-dimethyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide, used for the treatment of obesity or diabetes | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858631-B2 | Substituted pyrido [2,3-d] pyrimidinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-1551834-B1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20060235019-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2006-10-19 | — | — | US | disclosed |
| US-7034033-B2 | Substituted quinazolinone compounds | CHIRON CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060030573-A1 | Substituted quinazolinone compounds | BOYCE RUSTUM S | 2006-02-09 | — | — | US | disclosed |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION GLAXOSMITHKLINE | 2005-09-01 | — | — | US | disclosed |
| US-20050059662-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2005-03-17 | — | — | US | disclosed |
| US-20040019049-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235019-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC5R | HSD11B1 1356/4885 |
| US-20050059662-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | HSD11B1 3308/4885 |
| US-20040019049-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | HSD11B1 1985/4885 |
| US-20060030573-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | HSD11B1 2093/4885 |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | MC4R, MC5R, MC2R | HSD11B1 3113/4885 |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | MC4R, MC2R, MC3R | HSD11B1 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.